Skip to content

Quest Diagnostics

US · DGX #767 by market cap Listed 1996
258.28 -0.81 -0.31%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 5 in the most recent period (2026/Q4).
  • Total institutional ownership fell 0.3 percentage points.

Ownership vs. money flow

Diverging

Institutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
96.85% -0.30pp
Institutions
1,350 -5
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund81.78%
Public Company5.17%
Hedge Fund3.44%
Private Company2.08%
Government Pension Fund1.63%
Sovereign Wealth Fund1.32%
Family Office/Trust0.50%
Insurance Company0.42%
Individual/Insider0.38%
Other3.29%

Top holders as of 2026-09-30

BlackRock 8.41% · 9.25M sh
Vanguard Capital Management, LLC 7.14% · 7.85M sh
Vanguard Portfolio Management, LLC 5.56% · 6.11M sh
State Street Global Advisors 5.05% · 5.56M sh
T. Rowe Price Group, Inc. 4.56% · 5.02M sh
Boston Partners Global Investors, Inc. 4.22% · 4.64M sh
FMR 3.84% · 4.23M sh
Geode Capital Management, LLC 2.88% · 3.16M sh
J.P. Morgan Asset Management, Inc. 2.22% · 2.44M sh
Dimensional Fund Advisors 1.82% · 2.00M sh
EdgePoint Investment Group Inc. 1.91% · 2.10M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 38 buys · 10 sells

NameRoleStake
James Davis Chairperson & CEO 0.11%
Catherine Doherty Executive Vice President of Regional Businesses 0.07%
Michael Prevoznik General Counsel 0.04%
Michael Deppe Senior VP, Corporate Controller & Chief Accounting Officer 0.03%
Sam Samad Chief Financial Officer 0.03%
Timothy Main Independent Director 0.02%
Vicky Gregg Independent Director 0.02%
Karthik Kuppusamy Senior Vice President of Clinical Solutions 0.01%
Patrick Plewman Senior Vice President of Diagnostic Services 0.01%
Mark Delaney Chief Commercial Officer 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-08 Patrick Plewman Senior Vice President of Diagnostic Services Automatic Disposition -650 $257.34
2026-11-08 Patrick Plewman Senior Vice President of Diagnostic Services Derivative Exercise and Sale -11,067 $127.73–257.34
2026-11-02 Catherine Doherty Executive Vice President of Regional Businesses Other Acquisition +4,827 --
2026-11-02 Catherine Doherty Executive Vice President of Regional Businesses Derivative Exercise and Sale -22,105 $121.81–251.24
2026-11-02 Mark Delaney Chief Commercial Officer Other Acquisition +2,615 --
2026-11-02 Ramachandran Subu -- Other Acquisition +352 --
2026-11-02 Ramachandran Subu -- Other Derivative Acquisition +1,386 $248.61
2026-10-31 Ramachandran Subu -- Initial Statement of Beneficial 0 --
2026-10-25 Gary Pfeiffer Independent Director Automatic Disposition -1,203 $243.00
2026-10-25 Gary Pfeiffer Independent Director Intent to Sell (Form 144) -1,203 $243.00
2026-10-20 Patrick Plewman Senior Vice President of Diagnostic Services Other Acquisition +41 $235.94
2026-10-20 Timothy Main Independent Director Other Acquisition +18 $235.94
2026-10-20 Robert Carter Independent Director Other Acquisition +10 $235.93
2026-10-20 Vicky Gregg Independent Director Other Acquisition +63 $235.94
2026-10-20 Wright Lassiter Independent Director Other Acquisition +6 $235.96
2026-10-20 Sam Samad Chief Financial Officer Other Acquisition +90 $235.94
2026-10-20 Mark Delaney Chief Commercial Officer Other Acquisition +25 $235.94
2026-10-20 Karthik Kuppusamy Senior Vice President of Clinical Solutions Other Acquisition +33 $235.94
2026-09-30 Timothy Wentworth Director Other Derivative Acquisition +135 --
2026-08-31 James Davis Chairperson & CEO Automatic Disposition -10,000 $242.72

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:27 · For reference only, not investment advice and not tailored to your situation.

Quest Diagnostics discussion 0 comments

Add a comment